https://rijournals.com/public-health-and-pharmacy/

RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(2): 30-33, 2024

RIJPP Publications

ISSN ONLINE: 1115-8689

ISSN PRINT 1597-8559

https://doi.org/10.59298/RIJPP/2024/323033

The Role of Biomarkers in Personalized Cancer Treatment

Nassimbwa Kabanda D.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Biomarkers are vital instruments in modern medicine, providing information about biological processes and disease progression. Biomarkers in oncology have had a substantial impact on the development of personalised cancer treatments by predicting therapy responses and outcomes. The study investigates the different types of biomarkers, such as diagnostic, prognostic, and predictive biomarkers, and their function in precision medicine. Personalised cancer treatment, which is guided by biomarker testing, improves patient outcomes by adapting medicines to individual genetic profiles. However, obstacles such as biomarker validation, resistance to targeted medicines, and regulatory barriers persist. Overcoming these obstacles will propel future advances in biomarker-driven oncology.

Keywords: Biomarkers, personalized medicine, cancer, precision oncology, diagnostic biomarkers.

INTRODUCTION

Biomarkers are variable indicators used to observe biological processes that may lead to diseases. They are important in clinical research and can help determine the extent of system change, disease progression, causative agents, and treatment response. Targeted therapies for patients with specific biomarkers are highly valuable as they focus on the disease biology of specific populations [1]. However, it is important to note that biomarker presence does not guarantee disease presence; the extent of the presence may sometimes grossly underestimate or overestimate some aspect of the disease's presence or risk, and other intersubject differences in disease presence, response to treatment, or final outcome cannot be captured fully by a single or even a set of biomarkers. Heterogeneity within these 'biomarker positive' groups is well known to occur, especially for diseases such as cancers. Also, the decisions regarding the standards for prioritizing what the 'best' biomarkers are in clinical decision-making are still an area of research. It is important to recognize and address all these areas of biomarker utility and limitation to better understand where to apply them in the development of therapeutic strategies. In this section, we will review the conventional and cutting-edge application of biomarkers in both the diagnosis and treatment of various disease states, notable for both their differences and similarities. Following this is a more thorough discussion of how biomarkers impact clinical decision-making, especially in oncology [2].

DEFINITION AND TYPES OF BIOMARKERS

Biomarkers can be defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. There are several classes of biomarkers, including diagnostic biomarkers, which provide information on the nature or stage of a disease or physiological state; prognostic biomarkers, which show the likely outcome in the absence of therapy and/or relate to the natural history of a disease; predictive biomarkers, which can predict the likely effect of a particular treatment; and pharmacodynamic biomarkers, which are used to assess the efficacy of therapy. The diagnostic biomarkers are extensively used in oncology by providing information about the presence, type, and stage of cancer [3]. To illustrate concepts, examples of diagnostic, prognostic, predictive, and pharmacodynamic biomarkers are provided. The discovery of new and valid biomarkers can greatly impact research and personalized therapy. Changes in cancer therapy with targeted drugs and antibodies have created a need for valid molecular

targets. Mass spectrometry and omics sciences offer opportunities to identify biomarkers in tumor and serum samples. Validation of these biomarkers can drive further research and clinical applications [4].

IMPORTANCE OF PERSONALIZED CANCER TREATMENT

Personalized or precision medicine refers to the use of patient-specific information, including genetic, environmental, and lifestyle factors, in the diagnosis of a disease and the tailoring of therapies to its precise diagnosis. Personalized treatment strategies can be effective in cancer for predicting a response to treatment and for determining which treatment regimens are less likely to have a favorable response, thereby preventing the adverse effects of ineffective treatment. In the past few years, several cancer drugs have been developed and are marketed with labeled indications based on the presence of certain tumor biomarkers. A biopsy is performed to collect tumor tissue or blood, which can be sequenced to identify certain tumor mutations, and therapies are administered based on these results. Personalized treatment of cancer guided by biomarkers can potentially improve patient outcomes, reduce the cost of cancer care, and sustain healthcare system resources [5]. Precision oncology approaches aim to understand tumor heterogeneity, measure it, and assess its implications on therapy selection. Tumors can evolve differently from individual to individual; in each individual, different tumor clones can develop over time. Targeting multiple mutations found in different clones increases the likelihood of eradicating the tumor. The inclusion of numerous targets in the molecules allows for the structuring of therapeutic strategies intended to conquer the emergence of resistance. In the United States, biomarker testing for patients is currently reimbursed by Medicare, Medicaid, or private insurance companies. In the past decade, several new personalized cancer treatments have received approval for diseases including lung cancer, melanoma, lymphoma, acute myeloid leukemia, and colorectal cancer. This trend is predicted to continue, and more drugs are expected to be approved. The advances in the understanding of tumor biology are leading to the expansion of biomarker-based clinical trials [6].

BENEFITS OF PERSONALIZED TREATMENT

Cancer therapy is increasingly personalized, providing tailored treatment based on biomarker status. This approach leads to higher tumor response rates and improved survival outcomes. It also reduces trial-and-error treatment, minimizes adverse reactions, and saves healthcare resources. Matching a drug to the patient enhances adherence to treatment and allows for combined sequential therapies. Early detection of drug resistance is crucial, and generic tumors can be easily incorporated into routine practice [7].

EXAMPLES OF BIOMARKER-DRIVEN THERAPIES

Finding patients who will benefit the most from your drug is not a new idea. Penicillin is often cited as the first successfully targeted therapy. The challenge has become to design fixed combinations crafted at the molecular level. The best examples in solid tumors are ALK fusion in non-small cell lung cancer for crizotinib, EGFR mutations in non-small cell lung cancer for gefitinib and erlotinib, and BRAFV600E mutation in melanoma for vemurafenib and cobimetinib or dabrafenib and trametinib. The groundbreaking paper outlined the uncomplicated strategy to select patients to benefit from targeted therapies. With a multiplex assay, they were able to identify the presence of the EML4-ALK fusion gene in approximately 50% of the lung cancer specimens. Since then, similar disruptive tests have been developed for companion diagnostic purposes. Chromogenic in situ hybridization, immunohistochemistry, and RT-PCR are still common techniques, but most tests use fluorescent or chromogenic in situ hybridization. Interest in next-generation sequencing has been growing, especially in programs including basket trials. Given the new diagnostic opportunities, one of the next critical steps is the use of blood-based tests. These are associated with less patient suffering and less risk. The decision to discontinue tissue-based biopsies in a prospective clinical trial was driven by the high degree of concordance between the two tests. Two common approaches to identifying targets in solid tumors have been pursued. The first is the identification of predictive molecular markers—a specific change in the tumor's genome, transcriptome, or proteome. Probably any signal-to-noise assay yields a pool of potential targets. The classical next step is testing and validation in the clinical setting. If the target is identified and validated in a clinical cohort, the development of a dedicated clinical trial will ensue, approaching exclusively the identified subpopulation. To give you a flavor of how much these biomarker-driven, mostly independent molecular pathways have changed the expectations in the field of cancer, here are a series of case reports. This collection of examples demonstrates the critical ability of drug development out of clinical situations. Each is in a targeted disease setting but spreads around the hallmarks of cancer types. The proof of the success of all of these is supported, predominantly by either a prespecified adaptive trial design or in three cases by a randomized trial [8].

HER2-POSITIVE BREAST CANCER

Background: HER2 is a gene that can contribute to breast cancer development. When breast cancer is classified as "HER2-positive," it means the gene is overactive, resulting in an excess of the HER2 protein

on tumor cells. This leads to more aggressive growth and a higher risk of recurrence. Historically, HER2-positive breast cancer was difficult to treat, but precision medicine has brought about targeted therapies that have significantly improved patient survival. Clinical trials have shown that combining targeted therapy with chemotherapy can increase the time patients live without cancer progression by approximately 25%. Biomarker testing has revolutionized oncology by allowing for personalized precision medicine. For patients with HER2-positive breast cancer, biomarkers help determine the most suitable treatment and predict treatment outcomes. While biomarker testing has greatly improved the outlook for HER2-positive breast cancer, there is still room for improvement in long-term responses to targeted therapies [9].

CHALLENGES AND FUTURE DIRECTIONS

Although the number of FDA-approved targeted drugs is growing steadily, their clinical application is still limited. This fact highlights the remaining challenges in establishing personalized medicine in the clinical setting. Perhaps the most intricate obstacles are those related to individual biomarkers. First, the implementation of a newly discovered biomarker is inevitably hampered by the complexity of its clinical validation. As a result of this laborious process, only a few validated biomarkers reach the clinic every year. Furthermore, the establishment of general and stringent guidelines on how novel biomarkers should be discovered, prioritized, and validated is still missing [10]. Another issue is related to the regulatory hurdles that disfavor already established targeted strategies incorporating off-label drugs. Thus, the economic factor has a fundamental role in the hesitant approval of an expanded list of targeted therapies. Finally, biomarker detection methods and techniques have limited implementation due to a lack of accuracy and/or inconsistency. Parameters such as intra- and intertumoral heterogeneity should be taken into account when testing guiding molecules for a single individual. In conclusion, targeted therapy is evolving and is now linked with personalized medicine, at least in some medical conditions. However, several obstacles remain for generalized use. Future challenges include the identification of new tumor-specific alterations in target and associated resistance mechanisms. If the field of molecularly targeted therapy has opened new perspectives, a multidisciplinary approach is needed for clinical advancement [11].

OVERCOMING RESISTANCE TO TARGETED THERAPIES

Unfortunately, despite substantial advances in understanding the underlying genetic and molecular drivers of cancer, tumors find ways to bypass the effects of these drugs, a process described as resistance. Resistance may develop by reactivation of the signaling pathways intended to be inhibited by these compounds, due to redundancy or compensatory effects among the molecules within the cancer cells. Or resistance may occur by activation of alternative, parallel pathways that circumvent the intended target. In addition, some malignant cells also activate survival pathways. Although the bulk of the targeted therapies await further investigation, we know that the landscape of drug resistance is extremely complex and predicated by a variety of molecular and cellular mechanisms. Consequently, cancer cells may use multiple mechanisms to sustain cell survival and growth. Thus, a thorough understanding of the possible resistance mechanisms would allow the development of more effective second-line inhibitors that target different points in the same or related pathways, and hence abolish potential strategies of adaptation of the cancer cells. Even more important for the long term, this understanding would guide the initiation of the development of biomarkers able to identify patients exhibiting resistance even before treatment begins and help direct these patients to other therapeutic choices. In clinical trials, upcoming new strategies designed to improve the efficacy of targeted agents include combining them, or with conventional treatment choices, in the hope of a more durable clinical response rate. The development of new formulations for targeted therapy agents is another appealing strategy, to enhance tumor selectivity, solubility, and pharmacokinetic properties, and to reduce systemic toxicities. Also, small molecular inhibitors are entering clinical trials to avoid the emergence of secondary mutations, targeting more than one kinase at a time, with the concept of inducing more cell stress and thus hopefully a greater antitumor effect while minimizing resistance. Randomized phase II selection of concomitant versus sequential treatment strategies is ongoing for many of the currently emerging new compounds to be tested to help guide drug development from an optimal perspective, considering patient outcomes. The use of surrogate biomarkers in this setting would aid considerably in better interpreting the clinical data. In parallel to the refinement of clinically effective treatments, mechanistic and functional work, as well as the reevaluation of crucial oncogenic pathways, is warranted to develop better compounds over time; this is true no matter the tempo of drug development [12].

CONCLUSION

Biomarkers play a critical role in advancing personalized cancer treatment by enabling more accurate diagnosis, prognosis, and therapeutic interventions. Their ability to predict treatment responses has led

to better outcomes for patients with cancers like lung cancer, breast cancer, and melanoma. Despite the progress, challenges such as drug resistance and the complexity of biomarker validation limit their broader clinical application. Continued research into the molecular mechanisms of cancer and the refinement of biomarker testing techniques are essential for overcoming these obstacles, ensuring that precision oncology reaches its full potential in improving cancer care.

REFERENCES

1. Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer—from biology to medicine. Nature reviews Clinical oncology. 2021 Aug;18(8):506-25.
2. Chan LK, Tsui YM, Ho DW, Ng IO. Cellular heterogeneity and plasticity in liver cancer. InSeminars in cancer biology 2022 Jul 1 (Vol. 82, pp. 134-149). Academic Press.
3. Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, Geissler J, Husereau D, Martinez-Lopez I, Normanno N, Reis-Filho JS. Delivering precision oncology to patients with cancer. Nature medicine. 2022 Apr;28(4):658-65.
4. Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Roselló S, Fleitas T, Roda D, Cervantes A. Personalized medicine: recent progress in cancer therapy. Cancers. 2020 Apr 19;12(4):1009. mdpi.com
5. Sarhadi VK, Armengol G. Molecular biomarkers in cancer. Biomolecules. 2022 Jul 23;12(8):1021.
6. Lin GA, Coffman JM, Phillips KA. The State of State Biomarker Testing Insurance Coverage Laws. JAMA. 2024 May 13.
7. Ryan ÉJ, Creavin B, Sheahan K. Delivery of personalized care for locally advanced rectal cancer: incorporating pathological, molecular genetics, and immunological biomarkers into the multimodal paradigm. Frontiers in Oncology. 2020 Aug 14; 10:1369.
8. Soltabayeva A, Ongaltay A, Omondi JO, Srivastava S. Morphological, physiological and molecular markers for salt-stressed plants. Plants. 2021 Jan 27;10(2):243.
9. Normanno N, Apostolidis K, de Lorenzo F, Beer PA, Henderson R, Sullivan R, Biankin AV, Horgan D, Lawler M. Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. InSeminars in cancer biology 2022 Sep 1 (Vol. 84, pp. 293-301). Academic Press. academia.edu
10. Matuszczak M, Schalken JA, Salagierski M. Prostate cancer liquid biopsy biomarkers' clinical utility in diagnosis and prognosis. Cancers. 2021 Jul 5;13(13):3373.
11. Pal M, Muinao T, Boruah HP, Mahindroo N. Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges. Biomedicine & Pharmacotherapy. 2022 Feb 1; 146:112488.
12. Pérez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, García-Aranda M, De Las Rivas J. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resistance Updates. 2020 Dec 1; 53:100718.

CITE AS: Nassimbwa Kabanda D. (2024). The Role of Biomarkers in Personalized Cancer Treatment. RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(2):3-33. https://doi.org/10.59298/RIJPP/2024/323033